N.E.W. Advisory Services’s Acumen Pharmaceuticals ABOS Stock Holding History

N.E.W. Advisory Services’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-598	Closed	-$658	–	842
2025 Q1	$658	Buy	+598	New	+$854	﹤0.01%	887

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

KIA

Knollwood Investment Advisory Hunt Valley, Maryland $992M AUM 28.95% 1-Year Est. Return

Pathstone Holdings Englewood, New Jersey $25.1B AUM 22.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

N.E.W. Advisory Services's ABOS Position: Q2 2025 in Review

N.E.W. Advisory Services sold out of Acumen Pharmaceuticals (ABOS) in Q2 2025, closing a stake of 598 shares — an estimated $658 sold.

N.E.W. Advisory Services first reported a position in ABOS in Q1 2025 and held it in 1 quarter. The position peaked at $658 in Q1 2025. 71 funds tracked by Wall St. Rank hold ABOS as of Q2 2025.

N.E.W. Advisory Services reported no remaining Acumen Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
N.E.W. Advisory Services sold 598 Acumen Pharmaceuticals shares in Q2 2025, an estimated $658.
N.E.W. Advisory Services first reported a position in Acumen Pharmaceuticals in Q1 2025 and held it in 1 quarter.
N.E.W. Advisory Services's Acumen Pharmaceuticals position peaked at $658 in Q1 2025.
71 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q2 2025.

Based on N.E.W. Advisory Services's 13F filing for Q2 2025, filed 18 Aug 2025.